BI 706321 + midazolam

BI 706321 + midazolam is an experimental drug regimen combining BI 706321, a potent and selective small molecule inhibitor of Receptor-Interacting Protein Kinase 2 (RIPK2), with midazolam, a well-established benzodiazepine primarily used for its anxiolytic, sedative, and anticonvulsant properties. BI 706321 is in early clinical development for the treatment of Crohn’s disease and is under investigation for its safety, tolerability, pharmacokinetics, and potential for drug-drug interactions when administered alongside probe substrates like midazolam. The combination is used in clinical pharmacology studies to assess whether BI 706321 affects the pharmacokinetics of cytochrome P450 3A4 (CYP3A4) substrates (midazolam is a widely accepted probe for this pathway). Midazolam’s role in this combination is not therapeutic but investigative, as a pharmacokinetic probe to monitor the impact of BI 706321 on metabolic enzymes[1][4].

Other names

BI706321BI-706321BI 706321Dormicum